ARIUS Receives Six Key US Patents

Strengthens Intellectual Property Portfolio on Lead Programs and Antibody Assets

30-Nov-2006

ARIUS Research Inc. announced that it has received Notices of Allowance from the United States Patent and Trademark Office for patents on their lead antibody, ARH460-16-2, targeting the CD44 antigen implicated as markers of cancer stem cells in breast and prostate cancer plus separate patents covering antibodies to the CD63, CD59 and MCSP antigens.

The new patents cover the antibody molecules and various uses of each antibody and other similar antibodies to treat cancers such as ovarian, prostate and breast cancer. In addition, ARIUS has patent claims covering epitopes or specific parts of a cancer antigen target. According to ARIUS, this patent approach represents a large step up in value over more general target coverage because it is the epitope that determines what a cell will do when an antibody binds to it. In ARIUS' case, functional antibodies bind to epitopes that signal a cancer cell to die.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous